Sugi Predict

Sugi Predict / Compounds / SCHEMBL6806198

SCHEMBL6806198

SCHEMBL6806198

CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@@H]1O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.62
▸ LGALS8 O00214 1/20 0.62
▸ LGALS4 P56470 1/20 0.62
▸ MAPK1 P28482 2/20 0.56
▸ CD69 Q07108 1/20 0.49
▸ CHIA Q9BZP6 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ LGALS1 P09382 1/20 0.48
▸ LGALS7; LGALS7B P47929 1/20 0.48
▸ LGALS9 O00182 1/20 0.46
▸ FGF1 P05230 1/20 0.46
▸ FGF2 P09038 1/20 0.46
▸ VEGFA P15692 1/20 0.46
▸ HPSE Q9Y251 1/20 0.46
▸ AMY2A P04746 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6806201 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL34473199 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL29399861 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL19579354 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL17777302 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL18867406 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL29399259 0.98 LGALS3 (0.63) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL30097961 0.97 LGALS3 (0.59) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL9398176 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL17050874 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1CD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4742901-A1 METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS Globachem NV (BE) 2026-05-20 — — EP claimed
WO-2025012480-A1 METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS INBIOSE N.V. (BE) 2025-01-16 — — WO claimed
US-20230313253-A1 PRODUCTION OF GLCNAC CONTAINING BIOPRODUCTS IN A CELL INBIOSE N.V. (BE) 2023-10-05 — — US claimed
EP-4742901-A1 METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS Globachem NV (BE) 2026-05-20 — — EP disclosed
EP-4743567-A1 CELLULAR PRODUCTION OF LACTO-N-TRIOSE (LN3)-CONTAINING OLIGOSACCHARIDES Inbiose N.V. (BE) 2026-05-20 — — EP disclosed
CN-122029274-A Cell production of oligosaccharides comprising lacto-N-trisaccharide (LN 3) 因比奥斯公司 2026-05-12 — — CN disclosed
US-20250361477-A1 PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL INBIOSE NV (BE) 2025-11-27 — — US disclosed
US-20250345420-A1 CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION UNIV CORNELL (US) 2025-11-13 — — US disclosed
US-12350348-B2 Compounds and therapeutic uses thereof AVVINITY THERAPEUTICS LIMITED (GB/GB) (GB) 2025-07-08 — — US disclosed
US-20250215450-A1 VIABLE GALACTOSYLTRANSFERASE KNOCK-OUT SHEEP AND RELATED METHODS FIOS THERAPEUTICS LLC (US) 2025-07-03 — — US disclosed
US-20250188504-A1 PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL INBIOSE N.V. (BE) 2025-06-12 — — US disclosed
CN-116059313-A Dosing regimen and related compositions and methods 阿佩利斯制药有限公司 2023-05-05 — — CN disclosed
US-20230133641-A1 VIABLE GALACTOSYLTRANSFERASE KNOCK-OUT SHEEP AND RELATED METHODS FIOS THERAPEUTICS, LLC 2023-05-04 — — US disclosed
WO-2023076897-A1 VIABLE GALACTOSYLTRANSFERASE KNOCK-OUT SHEEP AND RELATED METHODS FIOS THERAPEUTICS, LLC (US) 2023-05-04 — — WO disclosed
CN-110831544-B Long-acting compstatin analogs, dosing regimens for compositions thereof, and medical uses thereof 阿佩利斯制药有限公司 2022-11-18 — — CN disclosed
WO-2022226420-A2 AN FC GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2022-10-27 — — WO disclosed
WO-2022115775-A2 CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION CORNELL UNIVERSITY (US) 2022-06-02 — — WO disclosed
US-20220162262-A1 NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2022-05-26 — — US disclosed
EP-3947417-A1 NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB) 2022-02-09 — — EP disclosed
US-20040058888-A1 Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides ALCHEMIA PTY LTD. (AU) 2004-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12350348-B2 Compounds and therapeutic uses thereof MYD88, MAVS, NFATC1 LGALS3 106/4885LGALS8 157/4885LGALS4 122/4885
US-20220162262-A1 NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF MAVS, MYD88, CD47 LGALS3 178/4885LGALS8 145/4885LGALS4 116/4885
US-20040058888-A1 Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides B4GALT1, B3GAT3, FUT5 LGALS3 28/4885LGALS8 65/4885LGALS4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback